United Therapeutics (NASDAQ:UTHR – Get Free Report) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $685.00 to $687.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 29.75% from the company’s previous close.
Several other analysts have also recently commented on UTHR. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.
Read Our Latest Analysis on United Therapeutics
United Therapeutics Price Performance
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the firm earned $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, analysts predict that United Therapeutics will post 26.63 EPS for the current fiscal year.
Insider Buying and Selling at United Therapeutics
In related news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $576.93, for a total transaction of $5,769,300.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,890,130.68. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 525,743 shares of company stock valued at $293,954,527 in the last ninety days. 8.60% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On United Therapeutics
Hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics during the fourth quarter valued at $293,418,000. Avoro Capital Advisors LLC raised its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the last quarter. Finally, Baillie Gifford & Co. bought a new position in shares of United Therapeutics in the 4th quarter worth about $157,390,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
